Your browser doesn't support javascript.
loading
Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.
Scavello, Francesco; Tedesco, Calogero C; Castiglione, Stefania; Maciag, Anna; Sangalli, Elena; Veglia, Fabrizio; Spinetti, Gaia; Puca, Annibale A; Raucci, Angela.
Afiliación
  • Scavello F; Unit of Experimental Cardio-Oncology & Cardiovascular Aging, Centro Cardiologico Monzino-IRCCS, Milan, 20138, Italy.
  • Tedesco CC; Unit of Biostatistics, Centro Cardiologico Monzino-IRCCS, Milan, 20138, Italy.
  • Castiglione S; Unit of Experimental Cardio-Oncology & Cardiovascular Aging, Centro Cardiologico Monzino-IRCCS, Milan, 20138, Italy.
  • Maciag A; Cardiovascular Research Unit, IRCCS MultiMedica, Milan, 20138, Italy.
  • Sangalli E; Cardiovascular Research Unit, IRCCS MultiMedica, Milan, 20138, Italy.
  • Veglia F; Unit of Biostatistics, Centro Cardiologico Monzino-IRCCS, Milan, 20138, Italy.
  • Spinetti G; Cardiovascular Research Unit, IRCCS MultiMedica, Milan, 20138, Italy.
  • Puca AA; Cardiovascular Research Unit, IRCCS MultiMedica, Milan, 20138, Italy.
  • Raucci A; Department of Medicine, Surgery & Dentistry, 'Scuola Medica Salernitana', University of Salerno, Baronissi, 84081, Italy.
Biomark Med ; 15(11): 785-796, 2021 08.
Article en En | MEDLINE | ID: mdl-34236256
Lay abstract Aging is the major risk factor for disease development. Long-living individuals (LLIs) are subjects older than 90 years that represent an invaluable model to study mechanisms underpinning longevity and healthy aging. Circulating levels of soluble receptor for advanced glycation end products (sRAGE) change with aging and can forecast the cardiovascular risk, which is reduced in centenarians. sRAGE is composed of two isoforms, the cleaved RAGE (cRAGE) and the secretory RAGE (esRAGE), that are known to inhibit the oxidative stress and inflammatory activities of their ligands such the advanced glycation end products (AGEs). In this study, we measured the plasmatic levels of both sRAGE isoforms and AGEs in LLIs (90­105 years) and control subjects (11­89 years). We found that cRAGE decreases with age in controls and LLIs. esRAGE increases in LLIs and AGEs increase in controls with age but decrease in LLIs. AGEs/esRAGE ratio and cRAGE were able to discriminate controls from LLIs. Hence, LLIs are characterized by a lower AGEs/sRAGE ratio, due to esRAGE increase and AGEs reduction that may explain their reduced cardiovascular and metabolic risk. Besides, circulating cRAGE could be considered a reliable marker of chronological age, while esRAGE a protective factor associated with longevity.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Receptor para Productos Finales de Glicación Avanzada Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Biomark Med Asunto de la revista: BIOQUIMICA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Receptor para Productos Finales de Glicación Avanzada Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Biomark Med Asunto de la revista: BIOQUIMICA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Italia